SIMCERE PHARMA

2096.HK experienced a sharp pullback after opening high, dipping from 13.30 to an intraday low of 12.43 in the afternoon session, closing at 12.62, down 3.88% from the previous close of 13.13. The stock's decline came as the earlier positive news of SANBEXIN's inclusion in the National Essential Medicines List was partially priced in, while the afternoon session saw focus shift to the financials: Q4 net profit surged 191.61% YoY to HKD 411.67 million, revenue grew 23.07% to HKD 2.31 billion, and EPS of 0.1609 rose 181.91% YoY. Despite strong fundamentals, the price remains 16.31% below its 52-week high of 15.08 and slightly above the 20-day MA (11.06) and 60-day MA (10.98), suggesting profit-taking outweighed earnings momentum. However, the stock is still up 6.95% YTD, with a PB of 3.11 and PE of 21.78, offering some valuation support.

Simcere Pharmaceutical opened lower but rallied sharply in the morning session, reaching HKD 13.18 by 10:13 BJT, up 5.1% from the previous close of HKD 12.54. The intraday low of HKD 12.62 occurred at the opening tick, followed by a swift rebound to a high of HKD 13.17, forming a trading range of approximately 4.4%. The catalyst was the inclusion of SANBEXIN in the 2026 National Essential Medicines List. Financially, Q4 2025 revenue hit HKD 2.306 billion, net profit HKD 411.7 million, up 23.07% and 191.61% YoY respectively, with EPS rising 181.91% to HKD 0.1609. The company currently trades at a PE of 22.73x and PB of 3.25x, with a total market cap of HKD 33.8 billion. While the earnings recovery is strong, the stock has previously appeared on top loser lists due to events like the oncology spin-off, and today's gain requires follow-through volume.

Simcere Pharmaceutical opened higher and rallied in the morning session, peaking at HKD 12.760, a 5.5% gain from the prior close of HKD 12.090, primarily driven by the inclusion of its CNS product SANBEXIN into the China 2026 National Essential Medicines List, which could significantly expand its primary care coverage. Financially, Q4 2025 EPS surged 181.9% YoY to HKD 0.1609, revenue grew 23.1% YoY to HKD 2.306 billion, and net profit soared 191.6% YoY to HKD 412 million, with net profit margin stable at 17.9%. Trading at HKD 12.730, the stock carries a P/E of 22x, P/B of 3.15x, and total market cap of ~HKD 32.8 billion. While the price has rebounded from the session low of HKD 12.290, it remains off the intraday high of HKD 12.760, suggesting residual selling pressure. Nonetheless, the stock still trades below several broker targets, with UBS maintaining a Buy rating, leaving room for valuation catch-up contingent on further earnings delivery.

先声药业今日高开高走，全天低开 11.68 港元后探底回升，盘中摸高 12.28 港元，收报 12.03 港元，涨幅 4.88%。主因是公司前一日宣布与斯坦福医学院达成特发性肺纤维化研究合作，叠加此前与勃林格殷格翰合作开发 TL1A/IL23p19 双靶抗体治疗炎症性肠病的进展，以及肿瘤子公司先声再明拟分拆上市的预期，增强了市场对其创新管线的信心。最新财报显示 Q4 2025 营收 23.06 亿港元，同比增 23.07%，净利润 4.12 亿港元，同比增 191.61%，净利率 17.86%，基本面强劲支撑股价。当前股价 12.03 港元，YTD 涨 1.95%，已站上 MA20（9.918 港元）和 MA60（11.181 港元），但距 52 周高点 15.08 港元仍跌 20.23%。不过 UBS 给予买入评级，目标价从 15.9 港元上调至 21.8 港元，而盘中一度冲高至 12.28 港元后有所回落，显示高位仍有抛压。

2096.HK rallied in the afternoon session to close at HKD 11.47, recovering approximately 3.8% from the morning low of HKD 11.05 and reaching an intraday high of HKD 11.59. The strength was fueled by the company's robust earnings momentum: net profit surged 191.61% YoY to HKD 412 million in Q4 2025, alongside a 181.91% YoY jump in EPS to HKD 0.1609 and 23.07% revenue growth, with net profit margin steady at 17.86%. While the stock trades at a PE of 19.8x and PB of 2.83x with a market cap of approximately HKD 29.46 billion, the full-day turnover rate was only 0.55%, suggesting limited buying conviction and leaving the stock's ability to hold above key moving averages uncertain.